HUTCHMED (China) Limited (HK:0013)
:0013
Top Page
HUTCHMED (China)
(0013)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$22.50
▲(6.23% Upside)
Action:ReiteratedDate:03/07/26
The score is held back mainly by weak cash generation and negative operating profitability in 2025, despite a conservatively levered balance sheet. Technicals also signal a continuing downtrend (below major DMAs, negative MACD). Valuation is a relative positive due to the low P/E, but it does not fully offset the operating and cash-flow concerns.
Positive Factors
Conservative balance sheet
Low leverage and an expanding equity base provide durable financial flexibility. This reduces refinancing and interest-rate risk, supporting continued R&D and commercialization investment during periods of operational volatility and giving the company time to stabilize cash flow without immediate capital markets pressure.
Negative Factors
Weak cash generation
Recurring cash burn undermines the firm’s self-funding ability for trials and commercialization. Over the medium term this increases likelihood of external financing, which could be dilutive or restrictive, and constrains flexibility to invest in pipeline or commercial expansion without clear cash-flow recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and an expanding equity base provide durable financial flexibility. This reduces refinancing and interest-rate risk, supporting continued R&D and commercialization investment during periods of operational volatility and giving the company time to stabilize cash flow without immediate capital markets pressure.
Read all positive factors
HUTCHMED (China) (0013) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$20.55B
Dividend YieldN/A
Average Volume (3M)7.40M
Price to Earnings (P/E)5.0
Beta (1Y)0.90
Revenue Growth-1.78%
EPS GrowthN/A
CountryHK
Employees1,811
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding872,327,640
10 Day Avg. Volume5,279,510
30 Day Avg. Volume7,396,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.84
Price to Sales (P/S)4.14
P/FCF Ratio-28.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$30.66Price Target Upside44.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$639.14M
HUTCHMED (China) Business Overview & Revenue Model
Company Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The c...
How the Company Makes Money
HUTCHMED makes money through a combination of product sales, collaborations, and licensing agreements. The company's revenue streams include the commercialization of its proprietary drugs, particularly in the oncology sector, where it markets and ...
HUTCHMED (China) Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 602.20M | 549.32M | 630.20M | 838.00M | 426.41M | 356.13M |
| Gross Profit | 53.76M | 212.48M | 281.32M | 151.55M | 115.31M | 97.89M |
| EBITDA | -7.49M | -41.33M | 14.11M | 67.27M | -401.11M | -321.13M |
| Net Income | 466.88M | 457.58M | 37.73M | 100.78M | -360.83M | -194.65M |
Balance Sheet | ||||||
| Total Assets | 1.78B | 1.75B | 1.27B | 1.28B | 1.03B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.36B | 1.37B | 836.11M | 886.34M | 631.00M | 1.01B |
| Total Debt | 93.44M | 97.88M | 89.82M | 86.13M | 27.01M | 38.98M |
| Total Liabilities | 534.02M | 501.77M | 502.34M | 536.39M | 392.57M | 333.15M |
| Stockholders Equity | 1.23B | 1.24B | 759.93M | 730.54M | 610.37M | 986.89M |
Cash Flow | ||||||
| Free Cash Flow | -49.66M | -78.92M | -17.44M | 186.65M | -305.26M | -220.98M |
| Operating Cash Flow | -32.56M | -64.75M | 497.00K | 219.26M | -268.60M | -204.22M |
| Investing Cash Flow | -73.03M | -29.45M | -96.06M | -291.14M | 296.59M | -306.32M |
| Financing Cash Flow | 11.22M | 7.85M | -30.67M | 48.66M | -82.76M | 650.03M |
HUTCHMED (China) Technical Analysis
Positive
21.18
Price Trends
22.81
Positive
22.58
Positive
23.97
Negative
Market Momentum
0.28
Negative
58.63
Neutral
79.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0013, the sentiment is Positive. The current price of 21.18 is below the 20-day moving average (MA) of 22.59, below the 50-day MA of 22.81, and below the 200-day MA of 23.97, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 58.63 is Neutral, neither overbought nor oversold. The STOCH value of 79.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0013.
HUTCHMED (China) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$232.88B | 35.71 | 16.09% | 0.97% | 8.68% | 0.82% | |
70 Outperform | HK$31.10B | 11.61 | 14.47% | 4.09% | -0.45% | 9.00% | |
63 Neutral | HK$33.84B | 19.33 | 8.60% | 2.26% | 11.78% | 19.06% | |
57 Neutral | HK$74.76B | 14.15 | 7.02% | 1.69% | -1.12% | 76.16% | |
55 Neutral | HK$20.55B | 4.97 | 41.38% | ― | -1.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$13.42B | 292.71 | 0.57% | ― | 29.21% | 80.37% |
* Healthcare Sector Average
HK:0013
HUTCHMED (China)
23.64
1.09
4.83%
HK:0867
China Medical System Holdings
14.09
6.90
95.88%
HK:1513
Livzon Pharmaceutical Group
28.76
3.62
14.38%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.74
5.75
41.14%
HK:3692
Hansoh Pharmaceutical Group Company Limited
38.40
16.50
75.34%
HK:6185
CanSino Biologics, Inc. Class H
33.50
3.00
9.84%
HUTCHMED (China) Corporate Events
HUTCHMED Sets March 5 Board Meeting to Approve 2025 Annual Results
Feb 6, 2026
HUTCHMED (China) Limited has scheduled a board meeting for March 5, 2026 to approve and release its audited financial results for the year ended December 31, 2025, with the announcement to be published that evening in Hong Kong. Following the resu...
HUTCHMED’s Savolitinib Combo Shows Phase III Success in EGFR-Mutated Lung Cancer
Jan 14, 2026
HUTCHMED highlighted the publication in The Lancet of Phase III SACHI trial results, which show that combining its MET inhibitor savolitinib (ORPATHYS®) with AstraZeneca’s osimertinib (TAGRISSO®) significantly improves progression-...
HUTCHMED’s Sovleplenib Hits Phase III Goal in Warm Autoimmune Hemolytic Anemia Trial in China
Jan 7, 2026
HUTCHMED announced that the Phase III registration part of its ESLIM-02 trial in China for sovleplenib, an oral spleen tyrosine kinase (Syk) inhibitor, in adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA) met its...
HUTCHMED Advances Surufatinib Combo into Phase III Trial for Metastatic Pancreatic Cancer in China
Jan 5, 2026
HUTCHMED has initiated the Phase III stage of an ongoing Phase II/III clinical trial in China testing a four-drug combination—surufatinib, camrelizumab, nab-paclitaxel and gemcitabine—as a first-line therapy for treatment-naïve pa...
HUTCHMED Launches Global Clinical Trials for Innovative Cancer Therapy
Dec 17, 2025
HUTCHMED has initiated a global Phase I clinical development program for HMPL-A251, a first-in-class Antibody-Targeted Therapy Conjugate (ATTC) designed to treat patients with HER2-expressing solid tumors. This trial, conducted in the US and China...
HUTCHMED Expands Drug Coverage in China’s National and Commercial Insurance Lists
Dec 8, 2025
HUTCHMED (China) Limited has announced the renewal of its contract with the China National Healthcare Security Administration, ensuring continued inclusion of its drugs ELUNATE®, ORPATHYS®, and SULANDA® in the National Reimbursement...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.